Document is current
Any future updates will be listed below
-
Authors
Richardson, Tom G. https://orcid.org/0000-0002-7918-2040
Urquijo, Helena https://orcid.org/0000-0001-7549-6782
Howe, Laurence J. https://orcid.org/0000-0002-2819-9686
Hawkes, Gareth https://orcid.org/0000-0002-3367-789X
DePaolo, John https://orcid.org/0000-0002-6829-2594
Damrauer, Scott M. https://orcid.org/0000-0001-8009-1632
Frayling, Timothy M. https://orcid.org/0000-0001-8362-2603
Davey Smith, George https://orcid.org/0000-0002-1407-8314
-
Funding
Funding for this research was provided by:
Medical Research Council (MC_UU_00011/1)
- License Information
-
More Information
Article History
Received: 11 April 2024
Accepted: 18 January 2025
First Online: 19 March 2025
Declarations
:
: TGR and LJH are employees of GlaxoSmithKline outside of the work presented in this manuscript. All other authors declare no conflicts of interest. S.M.D receives research support to his institution from RenalytixAI and in kind support from Novo Nordisk, both outside of this work. SMD is named as a co-inventor on a government-owned US Patent application related to the use of genetic risk prediction for venous thromboembolic disease filed by the US Department of Veterans Affairs in accordance with Federal regulatory requirements.
